Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma.
Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.
Zangari
Maurizio
M
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. zangarimaurizio@uams.edu
Cavallo
Federica
F
Tricot
Guido
G
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D051231:Farnesyltranstransferase; D020123:Sirolimus